COMPASS Pathways has today announced that it will launch a Phase II clinical trial of its COMP360 psilocybin therapy in PTSD. The Phase II open label “COMP201” study will enrol 20 participants, and will initially take place at King’s College London. The study will follow the COMP360 protocol, including a fixed dose (25mg) administered in conjunction with psychological support.


Previous articleBright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
Next articleThe Missing Mushroom: Psychedelic Science and the Future of Psilocybin